April 2015 to June 2016, Ms. Galen served as Global Head, Communications and Public Affairs, for Shire plc, a biotechnology company, where she served as the lead communications and public affairs advisor on the successful $32B acquisition and integration of Baxalta. Previously, Ms. Galen led Global Communications for Novartis AG, based in Basel, Switzerland. During her 14 years with Novartis, Ms. Galen also served on several management boards in her capacity as Global Head, Communications and Advocacy, for Novartis Pharmaceuticals; as Vice President and Global Head, Oncology Affairs; Vice President and Global Head, Communications and External Affairs for Novartis Molecular Diagnostics; and Vice President, Corporate Communications, for US pharmaceuticals.
April 2015 to June 2016, Ms. Galen served as Global Head, Communications and Public Affairs, for Shire plc, a biotechnology company, where she served as the lead communications and public affairs advisor on the successful $32B acquisition and integration of Baxalta. Previously, Ms. Galen led Global Communications for Novartis AG, based in Basel, Switzerland. During her 14 years with Novartis, Ms. Galen also served on several management boards in her capacity as Global Head, Communications and Advocacy, for Novartis Pharmaceuticals; as Vice President and Global Head, Oncology Affairs; Vice President and Global Head, Communications and External Affairs for Novartis Molecular Diagnostics; and Vice President, Corporate Communications, for US pharmaceuticals.